Wolfgang Miesbach: How Laboratory Strategies Must Evolve to Meet Expanding Haemophilia Therapies
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared a post on LinkedIn:
”An inspiring morning at EAHAD 2026 in Dublin: Annette Bowyer’s talk ‘Monitoring factor treatment in 2026 and beyond’ highlighted how rapidly our laboratory strategies must evolve to keep pace with the expanding spectrum of haemophilia therapies:
Monitoring needs to be tailored to the molecule and treatment class – from SHL/EHL/UHL concentrates to FVIII mimetics, gene therapy and emerging non‑factor therapies.
One‑stage and chromogenic assays each have strengths and limitations; for some products, results can be systematically over‑ or underestimated, demanding product‑specific approaches and clear lab–clinic communication.
Global assays of haemostasis and specific monitoring of FVIII mimetics and anti‑TFPI therapies are becoming increasingly important, but still require harmonisation and standardisation.
With more subcutaneous and non‑replacement options, the frequency and goals of monitoring are changing – from traditional peak/trough levels to efficacy, safety, inhibitor risk and transgene expression over the long term.
For haemophilia centres, this means closer collaboration between clinicians and specialised laboratories, investment in assay validation, and updated protocols to ensure safe, effective and personalised care in the era of innovative therapies.”
Stay updated with Hemostasis Today.
-
Mar 5, 2026, 17:48Estelle Carminita։ What If the Origin of Platelet Dysfunction Starts in the Bone Marrow
-
Mar 5, 2026, 17:43Pierre Sabouret: The Best Antithrombotic Strategy in Patients with Atherosclerotic Stroke and AF
-
Mar 5, 2026, 17:37John Abraham։ The Role of Diagnostic Splenectomy in Unexplained Splenomegaly
-
Mar 5, 2026, 17:31Fayad Al-Haimus: Key Themes from the New 2026 AHA/ACC Guideline for Acute PE
-
Mar 5, 2026, 16:56From Chronic Pain with Every Step to Exercising Every Day – EHC
-
Mar 5, 2026, 15:51Samer Al Hadidi: Cytopenias and Infection Risk With BCMA-Directed Bispecific Antibodies
-
Mar 5, 2026, 15:35Ney Carter Borges: Cholesterol-Inflammation Fusion in Atherosclerosis
-
Mar 5, 2026, 15:33Nicolas Hubacz: How Stress Shapes Organ Development
-
Mar 5, 2026, 15:28Charles Greenberg: What If D-dimer Isn’t ‘Non-Specific’ At All?